Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New hope for tough breast cancers: major trial launches

NCT ID NCT06112379

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This large Phase 3 trial tests whether a new combination of drugs (datopotamab deruxtecan plus durvalumab) given before and after surgery works better than the current standard treatment for people with untreated triple-negative or hormone receptor-low/HER2-negative breast cancer. About 1,900 adults with stage II or III breast cancer will take part. The main goal is to see if the new approach helps keep cancer from coming back.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

1,902 people

The number who actually took part.

Started

Nov 2023

Expected to finish

Sep 2032

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participant must be ≥ 18 years, at the time of signing the ICF. * Histologically confirmed Stage II or III unilateral or bilateral primary invasive TNBC or hormone receptor-low/HER2-negative breast cancer * ECOG PS of 0 or 1 * Provision of acceptable tumor sample * Adequate bone marrow reserve and organ function * Contraceptive use by males or females should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies and aligned with protocol requirements. Exclusion criteria: * History of any prior invasive breast malignancy * History of another primary malignancy except for malignancy treated with curative intent with no known active disease within 5 years before randomization. * active or prior documented autoimmune or inflammatory disorders. * Evidence of distant disease. * Clinically significant corneal disease. * Has active or uncontrolled hepatitis B or C virus infection. * Known HIV infection that is not well controlled. * Uncontrolled infection requiring i.v. antibiotics, antivirals or antifungals; suspected infections; or inability to rule out infections. * Known to have active tuberculosis infection * Mean resting corrected QTcF interval \> 470 ms obtained from ECG * Uncontrolled or significant cardiac disease. * History of non-infectious ILD/pneumonitis * Has severe pulmonary function compromise * Any prior or concurrent surgery, radiotherapy or systemic anticancer therapy for TNBC or hormone receptor-low/HER2-negative breast cancer * For females only: is pregnant (confirmed with positive serum pregnancy test) or breastfeeding, or planning to become pregnant. * Female participants should refrain from breastfeeding from enrolment throughout the study and for at least 7 months after last dose of study intervention, or as dictated by local PI for SoC if longer. * Concurrent use of systemic hormone replacement therapy or oral hormonal contraception

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Breast cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Research Site

    Daphne, Alabama, 36526, United States

  • Research Site

    Prescott, Arizona, 86301, United States

  • Research Site

    Jonesboro, Arkansas, 72401, United States

  • Research Site

    Rogers, Arkansas, 72758, United States

  • Research Site

    Los Angeles, California, 90033, United States

  • Research Site

    Santa Barbara, California, 93105, United States

  • Research Site

    Santa Rosa, California, 92805, United States

  • Research Site

    Torrance, California, 90505, United States

  • Research Site

    Aurora, Colorado, 80045, United States

  • Research Site

    Longmont, Colorado, 80504, United States

  • Research Site

    Bridgeport, Connecticut, 06606, United States

  • Research Site

    New Haven, Connecticut, 06510, United States

  • Research Site

    Fort Myers, Florida, 33901, United States

  • Research Site

    Jacksonville, Florida, 32256, United States

  • Research Site

    St. Petersburg, Florida, 33705, United States

  • Research Site

    West Palm Beach, Florida, 33401, United States

  • Research Site

    Atlanta, Georgia, 30342, United States

  • Research Site

    Des Moines, Iowa, 50309, United States

  • Research Site

    Edgewood, Kentucky, 41017, United States

  • Research Site

    Louisville, Kentucky, 40202, United States

  • Research Site

    Baton Rouge, Louisiana, 70817, United States

  • Research Site

    Annapolis, Maryland, 21401, United States

  • Research Site

    Boston, Massachusetts, 02215, United States

  • Research Site

    Grand Rapids, Michigan, 49503, United States

  • Research Site

    Traverse City, Michigan, 49684, United States

  • Research Site

    Burnsville, Minnesota, 55337, United States

  • Research Site

    Minneapolis, Minnesota, 55407, United States

  • Research Site

    Columbia, Missouri, 65212, United States

  • Research Site

    Omaha, Nebraska, 68130, United States

  • Research Site

    East Brunswick, New Jersey, 08816, United States

  • Research Site

    New Brunswick, New Jersey, 08901, United States

  • Research Site

    Santa Fe, New Mexico, 87505, United States

  • Research Site

    New York, New York, 10065, United States

  • Research Site

    Charlotte, North Carolina, 28204, United States

  • Research Site

    Durham, North Carolina, 27710, United States

  • Research Site

    Winston-Salem, North Carolina, 27103, United States

  • Research Site

    Blue Ash, Ohio, 45242, United States

  • Research Site

    Eugene, Oregon, 97401, United States

  • Research Site

    Portland, Oregon, 97223, United States

  • Research Site

    Philadelphia, Pennsylvania, 19104, United States

  • Research Site

    Pittsburgh, Pennsylvania, 15212, United States

  • Research Site

    Chattanooga, Tennessee, 37404, United States

  • Research Site

    Nashville, Tennessee, 37203, United States

  • Research Site

    Austin, Texas, 78731, United States

  • Research Site

    Dallas, Texas, 75231, United States

  • Research Site

    Dallas, Texas, 75235, United States

  • Research Site

    Dallas, Texas, 75390-8843, United States

  • Research Site

    El Paso, Texas, 79902, United States

  • Research Site

    Flower Mound, Texas, 75028, United States

  • Research Site

    Fort Worth, Texas, 76104, United States

  • Research Site

    Houston, Texas, 77030, United States

  • Research Site

    San Antonio, Texas, 78240, United States

  • Research Site

    Webster, Texas, 77598, United States

  • Research Site

    Fairfax, Virginia, 22031, United States

  • Research Site

    Norfolk, Virginia, 23502, United States

  • Research Site

    Roanoke, Virginia, 24014, United States

  • Research Site

    Winchester, Virginia, 22601, United States

  • Research Site

    Tacoma, Washington, 98405, United States

  • Research Site

    East Melbourne, 3002, Australia

  • Research Site

    Feldkirch, 6807, Austria

  • Research Site

    Innsbruck, 6020, Austria

  • Research Site

    Linz, 4010, Austria

  • Research Site

    Salzburg, 5020, Austria

  • Research Site

    Antwerp, 2020, Belgium

  • Research Site

    Brasschaat, 2930, Belgium

  • Research Site

    Charleroi, 6060, Belgium

  • Research Site

    Ghent, 9000, Belgium

  • Research Site

    Leuven, 3000, Belgium

  • Research Site

    Libramont-Chevigny, 6800, Belgium

  • Research Site

    Brasília, 71681-603, Brazil

  • Research Site

    Curitiba, 80440-220, Brazil

  • Research Site

    Fortaleza, 60336-045, Brazil

  • Research Site

    Londrina, 86015-520, Brazil

  • Research Site

    Natal, 59075-740, Brazil

  • Research Site

    Porto Alegre, 90035-000, Brazil

  • Research Site

    Porto Alegre, 90035-903, Brazil

  • Research Site

    Ribeirão Preto, 14051-140, Brazil

  • Research Site

    Santo André, 09060-650, Brazil

  • Research Site

    São Paulo, 01246-000, Brazil

  • Research Site

    Taubaté, 12030-200, Brazil

  • Research Site

    Vitória, 29043-260, Brazil

  • Research Site

    Shumen, 9700, Bulgaria

  • Research Site

    Sofia, 1330, Bulgaria

  • Research Site

    Sofia, Bulgaria

  • Research Site

    Calgary, Alberta, T2N 5G2, Canada

  • Research Site

    Vancouver, British Columbia, VSZ 4E6, Canada

  • Research Site

    Barrie, Ontario, L4M 6M2, Canada

  • Research Site

    London, Ontario, N6A 5W9, Canada

  • Research Site

    Oshawa, Ontario, L1G 2B9, Canada

  • Research Site

    Toronto, Ontario, M5G 2M9, Canada

  • Research Site

    Lévis, Quebec, G6V 3Z1, Canada

  • Research Site

    Montreal, Quebec, H1T 2M4, Canada

  • Research Site

    Montreal, Quebec, H2X 0C1, Canada

  • Research Site

    Montreal, Quebec, H4A-3J1, Canada

  • Research Site

    Saint-Jérôme, Quebec, J7Z 5T3, Canada

  • Research Site

    Sherbrooke, Quebec, J1H 5N4, Canada

  • Research Site

    Montreal, H3T 1E2, Canada

  • Research Site

    Ottawa, K1H 8L6, Canada

  • Research Site

    Beijing, 100044, China

  • Research Site

    Bengbu, 233004, China

  • Research Site

    Changchun, 130021, China

  • Research Site

    Changsha, 410008, China

  • Research Site

    Chengdu, 610000, China

  • Research Site

    Guangzhou, 510060, China

  • Research Site

    Guangzhou, 510120, China

  • Research Site

    Hangzhou, 310009, China

  • Research Site

    Hangzhou, 310022, China

  • Research Site

    Harbin, 150049, China

  • Research Site

    Jinan, 250117, China

  • Research Site

    Linhai, 317000, China

  • Research Site

    Nanchang, 330009, China

  • Research Site

    Nanchang, 330029, China

  • Research Site

    Nanjing, 210008, China

  • Research Site

    Nanning, 530021, China

  • Research Site

    Shanghai, 200025, China

  • Research Site

    Shenyang, 110004, China

  • Research Site

    Shijiazhuang, 050020, China

  • Research Site

    Suining, 629000, China

  • Research Site

    Tianjin, 300000, China

  • Research Site

    Wuhan, 430022, China

  • Research Site

    Xi'an, 710061, China

  • Research Site

    Xintai, 54031, China

  • Research Site

    Zhaoqing, 526000, China

  • Research Site

    Zhengzhou, 450008, China

  • Research Site

    Avignon, 84918, France

  • Research Site

    Bayonne, 64100, France

  • Research Site

    Caen, 41076, France

  • Research Site

    Clermont-Ferrand, 63011, France

  • Research Site

    Limoges, 87000, France

  • Research Site

    Marseille, 13273, France

  • Research Site

    Montpellier, 34298, France

  • Research Site

    Nice, 06100, France

  • Research Site

    Paris, 75010, France

  • Research Site

    Reims, 51056, France

  • Research Site

    Toulouse, 31100, France

  • Research Site

    Vandœuvre-lès-Nancy, 54519, France

  • Research Site

    Villejuif, 94805, France

  • Research Site

    Augsburg, 86150, Germany

  • Research Site

    Berlin, 10967, Germany

  • Research Site

    Berlin, 13125, Germany

  • Research Site

    Dessau, 06847, Germany

  • Research Site

    Dresden, 01307, Germany

  • Research Site

    Erlangen, 91054, Germany

  • Research Site

    Essen, 45130, Germany

  • Research Site

    Esslingen am Neckar, 73730, Germany

  • Research Site

    Frankfurt am Main, 60431, Germany

  • Research Site

    Freiburg im Breisgau, 79110, Germany

  • Research Site

    Hamburg, 20246, Germany

  • Research Site

    Hanover, 30559, Germany

  • Research Site

    Heidelberg, 69120, Germany

  • Research Site

    Kiel, 24105, Germany

  • Research Site

    Mainz, 55131, Germany

  • Research Site

    Mannheim, 68167, Germany

  • Research Site

    München, 80637, Germany

  • Research Site

    Münster, 48149, Germany

  • Research Site

    Trier, 54290, Germany

  • Research Site

    Ulm, 89075, Germany

  • Research Site

    Hong Kong, 999077, Hong Kong

  • Research Site

    Budapest, 1122, Hungary

  • Research Site

    Kecskemét, 6000, Hungary

  • Research Site

    Miskolc, 3526, Hungary

  • Research Site

    Szekszárd, 7100, Hungary

  • Research Site

    Bengaluru, 560085, India

  • Research Site

    Delhi, 110029, India

  • Research Site

    Delhi, 110085, India

  • Research Site

    Kolkata, 700016, India

  • Research Site

    Kolkata, 700099, India

  • Research Site

    Marg Jaipur, 302004, India

  • Research Site

    Nagpur, 440001, India

  • Research Site

    Nashik, 422011, India

  • Research Site

    Thiruvananthapuram, 695011, India

  • Research Site

    Vadodara, 391760, India

  • Research Site

    Empoli, 50053, Italy

  • Research Site

    Lucca, 55100, Italy

  • Research Site

    Milan, 20132, Italy

  • Research Site

    Modena, 41124, Italy

  • Research Site

    Naples, 80131, Italy

  • Research Site

    Padova, 35128, Italy

  • Research Site

    Province of Macerata, 62100, Italy

  • Research Site

    Roma, 00168, Italy

  • Research Site

    Rozzano, 20089, Italy

  • Research Site

    Torino, 10126, Italy

  • Research Site

    Tricase, 73039, Italy

  • Research Site

    Udine, 33100, Italy

  • Research Site

    Akashi-shi, 673-8558, Japan

  • Research Site

    Akita, 010-8543, Japan

  • Research Site

    Bunkyō City, 113-8431, Japan

  • Research Site

    Chiba, 260-8717, Japan

  • Research Site

    Chūōku, 104-0045, Japan

  • Research Site

    Chūōku, 104-8560, Japan

  • Research Site

    Fukuoka, 811-1395, Japan

  • Research Site

    Fukushima, 960-1295, Japan

  • Research Site

    Gifu, 501-1194, Japan

  • Research Site

    Hidaka-shi, 350-1298, Japan

  • Research Site

    Hirakata-shi, 573-1191, Japan

  • Research Site

    Hiroshima, 730-0011, Japan

  • Research Site

    Hiroshima, 734-8551, Japan

  • Research Site

    Isehara-shi, 259-1193, Japan

  • Research Site

    Kashiwa, 227-8577, Japan

  • Research Site

    Kumamoto, 860-8556, Japan

  • Research Site

    Kurume-shi, 830-0011, Japan

  • Research Site

    Kyoto, 606-8507, Japan

  • Research Site

    Matsuyama, 791-0280, Japan

  • Research Site

    Nagoya, 460-0001, Japan

  • Research Site

    Nagoya, 466-8560, Japan

  • Research Site

    Nagoya, 467-0001, Japan

  • Research Site

    Niigata, 951-8566, Japan

  • Research Site

    Okayama, 700-8558, Japan

  • Research Site

    Osaka, 541-8567, Japan

  • Research Site

    Sapporo, 003-0804, Japan

  • Research Site

    Sapporo, 060-8648, Japan

  • Research Site

    Sendai, 980-8574, Japan

  • Research Site

    Shinagawa-ku, 142-8666, Japan

  • Research Site

    Shinjuku-ku, 160-0023, Japan

  • Research Site

    Shinjuku-ku, 162-8655, Japan

  • Research Site

    Sunto-gun, 411-8777, Japan

  • Research Site

    Tsu, 514-8507, Japan

  • Research Site

    Yokohama, 241-8515, Japan

  • Research Site

    George Town, 10990, Malaysia

  • Research Site

    Kuala Lumpur, 50586, Malaysia

  • Research Site

    Kuala Lumpur, 59100, Malaysia

  • Research Site

    Kuala Selangor, 62250, Malaysia

  • Research Site

    Kuching, 93586, Malaysia

  • Research Site

    Bialystok, 15-027, Poland

  • Research Site

    Bydgoszcz, 85-796, Poland

  • Research Site

    Gdynia, 81-519, Poland

  • Research Site

    Krakow, 31-501, Poland

  • Research Site

    Lodz, 93-338, Poland

  • Research Site

    Warsaw, 02-781, Poland

  • Research Site

    Singapore, 168583, Singapore

  • Research Site

    Daegu, 41404, South Korea

  • Research Site

    Goyang-si, 10408, South Korea

  • Research Site

    Seongnam, 13620, South Korea

  • Research Site

    Seoul, 02841, South Korea

  • Research Site

    Seoul, 03080, South Korea

  • Research Site

    Seoul, 03722, South Korea

  • Research Site

    Seoul, 05505, South Korea

  • Research Site

    Seoul, 06273, South Korea

  • Research Site

    Seoul, 06351, South Korea

  • Research Site

    Seoul, 06591, South Korea

  • Research Site

    Barcelona, 08036, Spain

  • Research Site

    Granada, 18016, Spain

  • Research Site

    Hospitalet deLlobregat, 08907, Spain

  • Research Site

    Madrid, 28007, Spain

  • Research Site

    Madrid, 28034, Spain

  • Research Site

    Santiago de Compostela, 15706, Spain

  • Research Site

    Seville, 41009, Spain

  • Research Site

    Zaragoza, 50009, Spain

  • Research Site

    Baden, CH-5405, Switzerland

  • Research Site

    Basel, 4031, Switzerland

  • Research Site

    Bern, 3010, Switzerland

  • Research Site

    Frauenfeld, 8501, Switzerland

  • Research Site

    Changhua, 500, Taiwan

  • Research Site

    Kaohsiung City, 82445, Taiwan

  • Research Site

    Taichung, 40447, Taiwan

  • Research Site

    Tainan, 704, Taiwan

  • Research Site

    Taipei, 10002, Taiwan

  • Research Site

    Taipei, 10449, Taiwan

  • Research Site

    Taipei, 112, Taiwan

  • Research Site

    Taoyuan, 333, Taiwan

  • Research Site

    Bangkok, 10210, Thailand

  • Research Site

    Bangkok, 10330, Thailand

  • Research Site

    Dusit, 10300, Thailand

  • Research Site

    Muang, 50200, Thailand

  • Research Site

    Songkhla, 90110, Thailand

  • Research Site

    Adapazarı, 54290, Turkey (Türkiye)

  • Research Site

    Ankara, 06010, Turkey (Türkiye)

  • Research Site

    Ankara, 06340, Turkey (Türkiye)

  • Research Site

    Ankara, 06520, Turkey (Türkiye)

  • Research Site

    Istanbul, 34722, Turkey (Türkiye)

  • Research Site

    Kayseri, 38039, Turkey (Türkiye)

  • Research Site

    Samsun, 55200, Turkey (Türkiye)

  • Research Site

    Birmingham, B15 2TG, United Kingdom

  • Research Site

    Cardiff, CF14 2TL, United Kingdom

  • Research Site

    Lancaster, LA1 4RP, United Kingdom

  • Research Site

    London, EC1A 7BE, United Kingdom

  • Research Site

    Northampton, NN1 5BD, United Kingdom

  • Research Site

    Oxford, OX3 7LE, United Kingdom

  • Research Site

    Taunton, TA1 5DA, United Kingdom

  • Research Site

    Hanoi, 100000, Vietnam

  • Research Site

    Ho Chi Minh City, 700000, Vietnam

  • Research Site

    Hồ Chí Minh, 700000, Vietnam

  • Research Site

    Vinh, 460000, Vietnam

More trials for these conditions

Other studies related to the condition(s) this trial covers.